United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) - dihydroergocornine mesylate 0.333 mg - a proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. the identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. it appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, alzheimer's dementia, senile onset, multi-infarct dementia). before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. particular care should be taken to exclude delirium and dementiform illness secon

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

novartis pharmaceuticals uk ltd - co-dergocrine mesilate - oral tablet - 4.5mg

Philippines - English - FDA (Food And Drug Administration)

novartis healthcare phils inc - co-dergocrine mesylate - tablet - 1mg+05ml

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

dafra pharma gmbh - artemether 180mg, lumefantrine 1080mg - co-artesiane is indicated for the treatment of malaria in children, caused by all forms of plasmodium including severe malaria caused by multiple drug resistant strains of p. falciparum. in case of a p. vivax malaria infection an additional treatment with primaquine may be required.

United States - English - NLM (National Library of Medicine)

carilion materials management - dihydroergocornine mesylate (unii: 42rx8kpw29) (dihydroergocornine - unii:ik4c1oc8ne), dihydroergocristine mesylate (unii: ds7cl18uam) (dihydroergocristine - unii:05d48lum4z), dihydro-.alpha.-ergocryptine mesylate (unii: z4i7bu58dn) (dihydro-.alpha.-ergocryptine - unii:202229ir8y), dihydro-.beta.-ergocryptine mesylate (unii: 79y4u49i29) (epicriptine - unii:5m64643b5u) - dihydroergocornine mesylate 0.333 mg - a proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. the identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. it appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, alzheimer's dementia, senile onset, multi-infarct dementia). before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. particular care should be taken to exclude delirium and dementiform illness secon

United States - English - NLM (National Library of Medicine)

cipla usa inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 0.5 mg - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 1 mg - for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia – see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

United States - English - NLM (National Library of Medicine)

proficient rx lp - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 1 mg - benztropine mesylate tablets, usp are indicated for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see precautions ) due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate tablets or to any component of the tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients. because of the atropine-like side effects, benztropine mesylate should be used with caution in pediatric patients over three years of age (see contraindications ).

United States - English - NLM (National Library of Medicine)

upsher-smith laboratories, llc - benztropine mesylate (unii: wmj8tl7510) (benztropine - unii:1nhl2j4x8k) - benztropine mesylate 0.5 mg - benztropine mesylate tablets are indicated for use as an adjunct in the therapy of all forms of parkinsonism. useful also in the control of extrapyramidal disorders [ except tardive dyskinesia - see precautions] due to neuroleptic drugs (e.g., phenothiazines). hypersensitivity to benztropine mesylate or to any component of the tablets. because of its atropine-like side effects, this drug is contraindicated in pediatric patients under three years of age, and should be used with caution in older pediatric patients.

United States - English - NLM (National Library of Medicine)

padagis us llc - dihydroergotamine mesylate (unii: 81axn7r2qt) (dihydroergotamine - unii:436o5hm03c) - dihydroergotamine mesylate 1 mg in 1 ml - dihydroergotamine mesylate injection, usp is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. there have been a few reports of serious adverse events associated with the coadministration of dihydroergotamine and potent cyp3a4 inhibitors, such as protease inhibitors and macrolide antibiotics, resulting in vasospasm that led to cerebral ischemia and/or ischemia of the extremities. the use of potent cyp3a4 inhibitors (i.e., ritonavir, nelfinavir, indinavir, erythromycin, clarithromycin, troleandomycin, ketoconazole, itraconazole) with dihydroergotamine is, therefore, contraindicated (see warnings, cyp3a4 inhibitors ). dihydroergotamine mesylate injection, usp should not be given to patients with ischemic heart disease (e.g., angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have clinical symptoms or findings consistent with coronary artery vasospasm including prinzmetal's variant